search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

A conditional mouse model for malignant mesothelioma.

Johan Jongsma ,
Erwin van Montfort ,
Marc Vooijs ,
John Zevenhoven ,
Paul Krimpenfort ,
Martin van der Valk ,
Marc van de Vijver ,
Anton Berns

Abstract

Malignant mesothelioma is a devastating disease that has been associated with loss of Neurofibromatosis type 2 (NF2) and genetic lesions affecting RB and P53 pathways. We introduced similar lesions in the mesothelial lining of the thoracic cavity of mice. Mesothelioma developed at high incidence in Nf2;Ink4a/Arf and Nf2;p53 conditional knockout mice with median survival times of approximately 30 and 20 weeks, respectively. Murine mesothelioma closely mimicked human malignant mesothelioma. Conditional Nf2;Ink4a/Arf mice showed increased pleural invasion compared to conditional Nf2;p53 mice. Interestingly, upon Ink4a loss in the latter mice median survival was significantly reduced and all tumors were highly invasive, suggesting that Ink4a loss substantially contributes to the poor clinical outcome of malignant mesothelioma.

More about this publication

Cancer cell

Volume 13
Issue nr. 3
Pages 261-71
Publication date 01-03-2008

Full text links

Publisher website (DOI) 10.1016/j.ccr.2008.01.030
Europe PubMed Central 18328429
Pubmed 18328429

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.